| Adam M Peterson, DO | |
|
301 Fisher St, Biloxi, MS 39534-2508 | |
| (228) 376-2273 | |
| Not Available |
| Full Name | Adam M Peterson |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 301 Fisher St, Biloxi, Mississippi |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659724177 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 28879 (Mississippi) | Primary |
| Entity Name | Singing River Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083893937 PECOS PAC ID: 3870405194 Enrollment ID: O20031104000435 |
News Archive
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
The lab of Kevin Foskett, PhD, the Isaac Ott Professor of Physiology at the University of Pennsylvania School of Medicine, has found a possible new target for fighting cystic fibrosis (CF) that could compensate for the lack of a functioning ion channel in affected CF-related cells. Their finding appears in the Journal of Clinical Investigation.
But news outlets report that the computer and phone systems designed to address those appeals have yet to be launched. So far, an estimated 22,000 requests for fixes have been submitted via the mail.
› Verified 7 days ago
| Entity Name | Singing River Gulfport |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861010159 PECOS PAC ID: 5294154829 Enrollment ID: O20201001001497 |
News Archive
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
The lab of Kevin Foskett, PhD, the Isaac Ott Professor of Physiology at the University of Pennsylvania School of Medicine, has found a possible new target for fighting cystic fibrosis (CF) that could compensate for the lack of a functioning ion channel in affected CF-related cells. Their finding appears in the Journal of Clinical Investigation.
But news outlets report that the computer and phone systems designed to address those appeals have yet to be launched. So far, an estimated 22,000 requests for fixes have been submitted via the mail.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adam M Peterson, DO 301 Fisher St, Biloxi, MS 39534-2508 Ph: (228) 376-2273 | Adam M Peterson, DO 301 Fisher St, Biloxi, MS 39534-2508 Ph: (228) 376-2273 |
News Archive
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
The lab of Kevin Foskett, PhD, the Isaac Ott Professor of Physiology at the University of Pennsylvania School of Medicine, has found a possible new target for fighting cystic fibrosis (CF) that could compensate for the lack of a functioning ion channel in affected CF-related cells. Their finding appears in the Journal of Clinical Investigation.
But news outlets report that the computer and phone systems designed to address those appeals have yet to be launched. So far, an estimated 22,000 requests for fixes have been submitted via the mail.
› Verified 7 days ago
Dr. Charles Milligan Holman Jr., M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 147 Reynoir St, Suite 306, Biloxi, MS 39530 Phone: 228-432-7817 Fax: 228-432-7818 |